Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
The DOI matches its Crossref record, with a small difference in title or year; 61 of the 61 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response to this therapy. METHODS: A total of 1050 black patients who had New York Heart Association class III or IV heart failure with dilated ventricles were randomly assigned to receive a fixed dose of isosorbide dinitrate plus hydralazine or placebo in addition to standard therapy for heart failure. The primary end point was a composite score made up of weighted values for death from any cause, a first hospitalization for heart failure, and change in the quality of life. RESULTS: The study was terminated early owing to a significantly higher mortality rate in the placebo group than in the group given isosorbide dinitrate plus hydralazine (10.2 percent vs. 6.2 percent, P=0.02). The mean primary composite score was significantly better in the group given isosorbide dinitrate plus hydralazine than in the placebo group (-0.1+/-1.9 vs. -0.5+/-2.0, P=0.01; range of possible values, -6 to +2), as were its individual components (43 percent reduction in the rate of death from any cause [hazard ratio, 0.57; P=0.01] 33 percent relative reduction in the rate of first hospitalization for heart failure [16.4 percent vs. 22.4 percent, P=0.001], and an improvement in the quality of life [change in score, -5.6+/-20.6 vs. -2.7+/-21.2, with lower scores indicating better quality of life; P=0.02; range of possible values, 0 to 105]). CONCLUSIONS: The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therapy for heart failure including neurohormonal blockers is efficacious and increases survival among black patients with advanced heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The primary outcome was a weighted score, but individual components of the outcome showed a difference favouring H-ISDN for all-cause mortality, first HHF, and change in quality of life score.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [79]
In the citing paper
“Digoxin may reduce the risk of HF hospitalization in patients with HFrEF treated with ACE-Is, irrespective of diabetes status.519”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [519]
Citations
Cites
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress
Cai, H., & Harrison, D. G. (2000) · Circulation Research · doi:10.1161/01.res.87.10.840 · Cited by 3,839
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Self-citationEffect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250502 · Cited by 2,833
Self-citationSuperoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor
Gryglewski, R. J., Palmer, R. M. J., & Moncada, S. (1986) · Nature · doi:10.1038/320454a0 · Cited by 2,400
Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142404 · Cited by 2,400
Self-citationEffect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,661
Cited by
Items 401–500 of 1,001
Management of Heart Failure in Patients with Chronic Kidney Disease
Ryan, D. K., Banerjee, D., & Jouhra, F. (2022) · European Cardiology Review · doi:10.15420/ecr.2021.33 · Cited by 53
McNamara, D. M., Taylor, A. L., Tam, S. W., Worcel, M., Yancy, C. W., Hanley‐Yanez, K., Cohn, J. N., & Feldman, A. M. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2014.04.016 · Cited by 43
Self-citationRohde, L. E. P., Palombini, D. V., Polanczyk, C. A., Goldraich, L. A., & Clausell, N. (2007) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2007.05.003 · Cited by 43
Cole, R. T., Gandhi, J., Bray, R. A., Gebel, H. M., Yin, M. T., Shekiladze, N., Young, A., Grant, A., Mahoney, I., Laskar, S. R., et al. (2017) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2017.11.003 · Cited by 43
Treatment of chronic heart failure: a comparison between the major guidelines
McMurray, J. J. V., & Swedberg, K. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl123 · Cited by 43
Organic nitrates in cardiovascular disease.
Bode‐Böger, S. M., & Kojda, G. (2005) · PubMed · Cited by 56
Bioactivation of organic nitrates and the mechanism of nitrate tolerance.
Klemenska, E., & Berȩsewicz, A. (2009) · PubMed · Cited by 57
Dulce, R. A., Yiginer, O., Gonzalez, D. R., Goss, G., Feng, N., Zheng, M., & Hare, J. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.412130 · Cited by 42
Echols, M. R., Felker, G. M., Thomas, K. L., Pieper, K. S., Garg, J., Cuffe, M. S., Gheorghiade, M., Califf, R. M., & O’Connor, C. M. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.003 · Cited by 42
Golwala, H. B., Thadani, U., Liang, L., Stavrakis, S., Butler, J., Yancy, C. W., Bhatt, D. L., Hernandez, A. F., & Fonarow, G. C. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000214 · Cited by 41
Self-citationWittkop, L., Smith, C. J., Fox, Z. V., Sabin, C. A., Richert, L. E., Aboulker, J.-P., Phillips, A. N., Chêne, G., Babiker, A. G., Thiébaut, R., et al. (2010) · Clinical Trials · doi:10.1177/1740774509356117 · Cited by 47
“Attempts to weight each component differently have already been made in cardiovascular disease field [14].”
BackgroundStudies in History and Philosophy of Biological and Biomedical Sciences
Winther, R. G., Millstein, R. L., & Nielsen, R. (2015) · Cited by 42
Chanduluru, H. K., & Sugumaran, A. (2021) · RSC Advances · doi:10.1039/d1ra04843k · Cited by 42
Krauser, D. G., Chen‐Tournoux, A., Tung, R. H., Anwaruddin, S., Baggish, A. L., & Januzzi, J. L. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.04.005 · Cited by 45
Matera, M. G., Martuscelli, E., & Cazzola, M. (2009) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2009.10.001 · Cited by 42
The Roles of Counseling Psychologists in Reducing Health Disparities
Tucker, C. M., Ferdinand, L. A., Mîrșu-Păun, A., Herman, K. C., Delgado-Romero, E. A., van den Berg, J. J., & Nielsen, J. J. (2007) · The Counseling Psychologist · doi:10.1177/0011000007301687 · Cited by 47
“These and other findings have prompted the recent development of controversial race-specific medications (Bloche, 2004; Taylor et al., 2004) and promoted a campaign of genetic research geared toward reducing and/or eliminating health disparities (Collins et al.”
BackgroundRacial Differences in 30-Day Mortality for Pulmonary Embolism
Ibrahim, S. A., Stone, R. A., Obrosky, D. S., Sartorius, J. A., Fine, M. J., & Aujesky, D. (2006) · American Journal of Public Health · doi:10.2105/ajph.2005.078618 · Cited by 42
Management of Heart Failure Patients with Reduced Ejection Fraction
Mann, D. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00028-7 · Cited by 51
Steg, P. G., James, S. K., Atar, D., Badano, L. P., Lundqvist, C. B., Borger, M. A., Mario, C. D., Dickstein, K., Ducrocq, G., Fernández‐Avilés, F., et al. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.10.014 · Cited by 91
Patient-Specific Stem Cells and Cardiovascular Drug Discovery
Mordwinkin, N. M., Lee, A. S., & Wu, J. C. (2013) · JAMA · doi:10.1001/jama.2013.282409 · Cited by 41
Taylor, A. L. (2015) · Current Heart Failure Reports · doi:10.1007/s11897-015-0252-x · Cited by 41
Self-citationRegulation of Endothelial Cell Tetrahydrobiopterin
Harrison, D. G., Chen, W., Dikalov, S., & Li, L. (2010) · Advances in pharmacology · doi:10.1016/b978-0-12-385061-4.00005-2 · Cited by 42
“When combined with hydralazine, isosorbide dinitrate improves outcome in subgroups of patientswith congestive heart failure (Taylor et al., 2004), but otherwise the organic nitrates have not provided survival benefit and use of these agents is often limited by the development of tolerance…”
BackgroundOffice management of heart failure in the elderly
Rich, M. W. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.12.019 · Cited by 41
Medicine and public health in a multiethnic world
Bhopal, R. (2009) · Journal of Public Health · doi:10.1093/pubmed/fdp069 · Cited by 53
The economics of heart failure care
Chen, W., Heidenreich, P. A., & Sandhu, A. T. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.01.010 · Cited by 46
The Use of Race and Ethnicity in Medicine: Lessons from the African-American Heart Failure Trial
Cohn, J. N. (2006) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2006.00068.x · Cited by 40
Self-citationKalogeropoulos, A. P., Georgiopoulou, V. V., Gheorghiade, M., & Butler, J. (2011) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2011.10.019 · Cited by 40
“As a result, the vast majority of HF clinical trials have employed linear dimensions or 2-dimensional (2D)-derived volumes and LVEF as a primary (in early-phase trials) or secondary (in Phase III trials) endpoint.(11,33) Aside from consistent underestimation of absolute values compared with CMR,(8) a major”
BackgroundLong-term management of end-stage heart failure
Habal, M. V., & Garan, A. R. (2017) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2017.07.003 · Cited by 46
“Moreover, owing to the mortality benefit amongst black patients with advanced (NYHA III and IV) HF demonstrated in the A-HeFT trial, hydralazine/ISDN should be added to standard therapies in all black patients who tolerate it hemodynamically.(38)”
BackgroundIribarne, A., DiScipio, A. W., Leavitt, B. J., Baribeau, Y. R., McCullough, J. N., Weldner, P. W., Huang, Y., Robich, M. P., Clough, R. A., Sardella, G. L., et al. (2018) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2018.04.121 · Cited by 40
“Ischemic heart disease continues to be the most common etiology for heart failure with reduced EF in industrialized nations, accounting for 50% to 65% of cases.(13,14) Despite the prevalence of ischemic coronary artery disease, recent data suggest that most patients hospitalized for new-onset heart failure do not rece…”
BackgroundImpact of a high‐dose nitrate strategy on cardiac stress in acute heart failure: a pilot study
Breidthardt, T., Noveanu, M., Potocki, M., Reichlin, T., Egli, P., Hartwiger, S., Socrates, T., Gayat, É., Christ, M., Mebazaa, A., et al. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02146.x · Cited by 40
Schade, D., Kotthaus, J., & Clement, B. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.005 · Cited by 44
Alternatives to transplantation in the surgical therapy for heart failure
Nicolini, F., & Gherli, T. (2008) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2008.11.003 · Cited by 40
Gadegbeku, C. A., Lea, J. P., & Jamerson, K. (2005) · Medical Clinics of North America · doi:10.1016/j.mcna.2005.05.003 · Cited by 41
“In support of the theory of reduced nitric oxide bioavailability, there is clinical evidence that African Americans who have congestive heart failure receive significant benefit from nitrovasodilator therapy [42].”
BackgroundKhazanie, P., Liang, L., Curtis, L. H., Butler, J., Eapen, Z. J., Heidenreich, P. A., Bhatt, D. L., Peterson, E. D., Yancy, C. W., Fonarow, G. C., et al. (2016) · Circulation: Heart Failure · doi:10.1161/circheartfailure.115.002444 · Cited by 39
“Moreover, the overall effectiveness of H-ISDN therapy in clinical practice may differ from that seen in clinical trial populations, which are carefully selected and receive protocol-driven care and follow-up.(1,3,10,11) In clinical practice, patients tend to be older, have a higher burden of comorbid illnesses, and ha…”
MethodSelf-citationThe Future of Heart Transplantation
KOBASHIGAWA, J. A. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04223.x · Cited by 42
“ACEI/ARB (101–103) 17 22 over 42 77 20% b-Blocker (104–107) 34 28 over 12 28 31% Aldosterone antagonist (108–110) 30 9 over 24 18 25% Hydralazine/nitrate (111) 43 25 over 10 21 NA CRT (112–115) 36 12 over 24 24 29%/22% ICD (116–118) 23 14 over 60 70 26%”
BackgroundChronic heart failure: an overview of conventional treatment versus novel approaches
Landmesser, U., & Drexler, H. (2005) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0371 · Cited by 46
Kong, Q., & Blanton, R. M. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.113.000575 · Cited by 39
Barr, D. A. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-11-200512060-00009 · Cited by 40
Pharmacogenomics and nutrigenomics: synergies and differences
GHOSH, D. K., Skinner, M. A., & Laing, W. A. (2007) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602590 · Cited by 39
“A recent example of a pharmacogenetics medicine is the targeting of BiDil (Taylor et al., 2004), used for treatment of heart failure, towards black African Americans, although in this case the use of race as a surrogate for genetics is debatable.”
BackgroundAdvances in management of heart failure
Heidenreich, P. A., & Sandhu, A. T. (2024) · BMJ · doi:10.1136/bmj-2023-077025 · Cited by 43
Li, H., Förstermann, U., Xia, N., Kuntić, M., Münzel, T. F., & Daiber, A. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.06.009 · Cited by 41
Personalized Cardiovascular Medicine Today
Blaus, A., Madabushi, R., Pacanowski, M. A., Rose, M., Schuck, R. N., Stockbridge, N., Temple, R., & Unger, E. F. (2015) · Circulation · doi:10.1161/circulationaha.114.009761 · Cited by 38
Current challenges in managing comorbid heart failure and COPD
Neder, J. A., Rocha, A., Alencar, M. C. N., Arbex, F. F., Berton, D. C., Oliveira, M. F., Sperandio, P. A., Nery, L. E., & O’Donnell, D. E. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1510319 · Cited by 39
“adrenergic and RAS blockade) [113] and in patients intolerant to”
BackgroundImpact of race on survival in pulmonary arterial hypertension: Results from the REVEAL registry
Medrek, S. K., Sahay, S., Zhao, C., Selej, M., & Frost, A. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.11.024 · Cited by 40
A pathophysiological compass to personalize antianginal drug treatment
Bertero, E., Heusch, G., Münzel, T. F., & Maack, C. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00573-w · Cited by 38
Jawa, A., Nachimuthu, S., Pendergrass, M. L., Asnani, S., & Fonseca, V. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1632 · Cited by 38
“The Third National Health and Nutrition Examination Survey showed higher cardiovascular disease risk factors among African-American women and children of both sexes than among white women and children of comparable socioeconomic status (31, 32).”
BackgroundTang, W. H. W., & Francis, G. S. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.015 · Cited by 38
Using explicit teaching to improve how bioscience students write to the lay public
Moni, R. W., Hryciw, D. H., Poronnik, P., & Moni, K. (2007) · AJP Advances in Physiology Education · doi:10.1152/advan.00111.2006 · Cited by 39
Shelton, R. J., Velavan, P., Nikitin, N. P., Coletta, A. P., Clark, A. L., Rigby, A. S., Freemantle, N., & Cleland, J. G. F. (2004) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2004.11.008 · Cited by 38
Johnson, A., Gong, Y., Wang, D., Langaee, T., Shin, J., Cooper-DeHoff, R., Schork, N., Binkley, P., Pepine, C., Johnson, J., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.194 · Cited by 38
The United States 2020 Census Data: Implications for Precision Medicine and the Research Landscape
Roman, Y. M. (2021) · Personalized Medicine · doi:10.2217/pme-2021-0129 · Cited by 38
Rush, C. J., Campbell, R. T., Jhund, P. S., Connolly, E. C., Preiss, D., Gardner, R. S., Petrie, M. C., & McMurray, J. J. V. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2015.03.013 · Cited by 44
Association of Vascular Risk Factors With Cognition in a Multiethnic Sample
Schneider, B. C., Gross, A. L., Bangen, K. J., Skinner, J. C., Benitez, A., Glymour, M. M., Sachs, B. C., Shih, R. A., Sisco, S., Manly, J. J., et al. (2015) · The Journals of Gerontology Series B: Psychological Sciences and Social Sciences · doi:10.1093/geronb/gbu040 · Cited by 39
“It is reported that conditions such as hypertension and congestive heart failure do not have the same response across ethnic groups (Taylor & Wright, 2005; Taylor et al., 2004) and treatment regimens tailored to blacks have been proposed.”
BackgroundReed, B. N., & Sueta, C. A. (2014) · Current Cardiology Reviews · doi:10.2174/1574884708666131117125508 · Cited by 42
Bress, A. P., King, J. B., Brixner, D. I., Kielhorn, A., Patel, H., Maya, J. F., Lee, V. C., BISKUPIAK, J. E., & Munger, M. A. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1701 · Cited by 37
Ethnicity in Pulmonary Arterial Hypertension
Medrek, S. K., & Sahay, S. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.08.1159 · Cited by 37
Personalized Management of Cardiovascular Disorders
Jain, K. K. (2017) · Medical Principles and Practice · doi:10.1159/000481403 · Cited by 40
Treatment of HF in an Era of Multiple Therapies
Bhatt, A. S., Abraham, W. T., Lindenfeld, J., Bristow, M. R., Carson, P. E., Felker, G. M., Fonarow, G. C., Greene, S. J., Psotka, M. A., Solomon, S. D., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.10.014 · Cited by 38
Self-citationHydralazine-induced Lupus: Maintaining Vigilance with Increased Use in Patients with Heart Failure
Finks, S. W., Finks, A. L., & Self, T. H. (2006) · Southern Medical Journal · doi:10.1097/01.smj.0000197121.12352.19 · Cited by 37
“It is noteworthy that SLE was not reported to have occurred in this patient population at the time of first publication.(16) Because of the relative 43% improvement in survival with hydralazine and isosorbide (hazard ratio, 0.”
BackgroundMethodResultInfluentialParodi, O., Maria, R. D., & Roubina, E. (2007) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32801194d4 · Cited by 37
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M. L., Konstam, M. A., MANCINI, D. M., Michl, K., et al. (2005) · Cited by 43
Self-citationMcMurray, J. J. V., Adamopoulos, S. N., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G. S., Fonseca, C., Sánchez, M. Á. G., et al. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.08.003 · Cited by 56
Genomics and the Conundrum of Race: Some Epistemic and Ethical Considerations
Maglo, K. N. (2010) · Perspectives in biology and medicine · doi:10.1353/pbm.0.0171 · Cited by 39
Sample size requirements for detecting treatment effect heterogeneity in cluster randomized trials
Yang, S., Li, F., Starks, M. A., Hernandez, A. F., Mentz, R. J., & Choudhury, K. R. (2020) · Statistics in Medicine · doi:10.1002/sim.8721 · Cited by 42
Genotype-Guided Hydralazine Therapy
Collins, K. S., Raviele, A. L. J., Elchynski, A. L., Woodcock, A., Zhao, Y., Cooper‐DeHoff, R. M., & Eadon, M. T. (2020) · American Journal of Nephrology · doi:10.1159/000510433 · Cited by 37
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
(2020) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2020.05.011 · Cited by 36
Ferdinand, K. C., Elkayam, U., MANCINI, D. M., Ofili, E., Piña, I. L., Anand, I. S., Feldman, A. M., McNamara, D. M., & Leggett, C. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.04.018 · Cited by 37
“In addition, in AHeFT, adding FD ISDNehydralazine to standard therapy decreased the number of hospitalizations and reduced length of hospital stay compared with standard therapy alone.(24,31) The relative risk of an HF-related hospitalization during the first 2 years of treatment was equal to placebo in VHeFT I and to…”
BackgroundMethodInfluentialSelf-citationHagos, G. K., Carroll, R. E., Kouznetsova, T., Li, Q., Toader, V., Fernandez, P. A., Swanson, S. M., & Thatcher, G. R. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0069 · Cited by 36
“The classic nitrate, ISDN, is important because it is now being used as a cardioprotective agent, expanding the clinical paradigm of nitrates to chronic, prophylactic therapy (15).”
BackgroundIntegrating Genomics and Neuromarkers for the Era of Brain-Related Personalized Medicine
Gordon, E. (2007) · Personalized Medicine · doi:10.2217/17410541.4.2.201 · Cited by 40
The Year in Heart Failure 2005
Massie, B. M., & Force, T. L. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.01.001 · Cited by 36
Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction
van Essen, B. J., Ceelen, D. C. H., Ouwerkerk, W., Teng, T. K., Tharshana, G. N., Hew, F. M., Butler, J., Zannad, F. M., Lam, C. S. P., Ezekowitz, J. A., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.054 · Cited by 41
Mentz, R. J., Bittner, V., Schulte, P. J., Fleg, J. L., Piña, I. L., Keteyian, S. J., Moe, G. W. P. L., Nigam, A., Swank, A. M., Onwuanyi, A., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.06.002 · Cited by 38
Jawa, A., Nachimuthu, S., Pendergrass, M., Asnani, S., & Fonseca, V. A. (2008) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2007.05.003 · Cited by 35
“Nevertheless, a combination of fixed dose of both isosorbide dinitrate and hydralazine has been approved by the FDA specifically for AA with heart failure, the decision being based on a large clinical trial (Bloche, 2004; Taylor et al., 2004).”
BackgroundAntihypertensive Medications in End‐Stage Renal Disease
Denker, M. G., & Cohen, D. L. (2015) · Seminars in Dialysis · doi:10.1111/sdi.12369 · Cited by 38
Sullivan, L. T., Randolph, T. C., Merrill, P., Jackson, L. R., Egwim, C., Starks, M. A., & Thomas, K. L. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.10.025 · Cited by 36
Race, Ethnicity, Ancestry, and Pharmacogenetics
Urban, T. J. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20168 · Cited by 41
Imaging left ventricular remodeling: targeting the neurohumoral axis
Shirani, J., & Dilsizian, V. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1244 · Cited by 36
GRK2 in the Heart: A GPCR Kinase and Beyond
Huang, Z. M., Gao, E., Chuprun, J. K., & Koch, W. J. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.5876 · Cited by 35
“In that trial, a combined therapy of isosorbide dinitrate and hydropazine, a vasodilator that also inhibits generation of O(2) - , decreased mortality by about 45% in African Americans with severe HF (85).”
Heart Failure and Kidney Disease
Grande, D., Gioia, M. I., Terlizzese, P., & Iacoviello, M. (2017) · Advances in experimental medicine and biology · doi:10.1007/5584_2017_126 · Cited by 38
Emerging role of pharmacogenomics in heart failure
McNamara, D. M. (2008) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3282fcd662 · Cited by 35
Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event
Schmidli, H., Roger, J., & Akacha, M. (2021) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2021.1895883 · Cited by 38
“Estimands that fit into this category have been used by Sampson et al. (2010), but may be difficult to interpret (Taylor et al. 2004).”
BackgroundMedical Therapy for Functional Mitral Regurgitation
Milwidsky, A., Mathai, S. V., Topilsky, Y., & Jorde, U. P. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.122.009689 · Cited by 38
Team-Based Care for Outpatients with Heart Failure
Creaser, J. W., DePasquale, E. C., Vandenbogaart, E., Rourke, D., Chaker, T., & Fonarow, G. C. (2015) · Heart Failure Clinics · doi:10.1016/j.hfc.2015.03.004 · Cited by 37
Heart failure in the ethnic minorities
Moe, G. W. P. L., & Tu, J. V. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328335fea4 · Cited by 40
Bermejo, J., Segovia, J., Heras, M., & Alfonso, F. (2007) · Revista Española de Cardiología · doi:10.1157/13099462 · Cited by 34
Interpretability of the European Heart Failure Self-care Behaviour scale
Wagenaar, K. P., Broekhuizen, B. D., Rutten, F. H., Strömberg, A., van Stel, H. F., Hoes, A. W., & Jaarsma, T. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s144915 · Cited by 39
“Based on the A-HeFT study, the following clinically relevant changes were determined: improved ($−5 units), unchanged (−4 up to 4 units), and worse ($5 units).(18) HF-related hospitalization was defined as unplanned overnight stay in a hospital due to progression of HF or directly related to HF.”
MethodNovaro, G. M., Asher, C. R., Bhatt, D. L., Moliterno, D. J., Harrington, R. A., Lincoff, A. M., Newby, L. K., Tcheng, J. E., Hsu, A. P., & Pinski, S. L. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.09.098 · Cited by 34
Future prospects of anticytokine therapy in chronic heart failure
von Haehling, S., & Anker, S. D. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.2.163 · Cited by 34
“Similarly, a fixed combination of isosorbide dinitrate and hydralazine has been suggested to be effective mostly in blacks with CHF [83].”
BackgroundMackenzie, I. S., Rutherford, D., & MacDonald, T. M. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2464 · Cited by 36
Oelze, M. W., Schuhmacher, S., & Daiber, A. (2010) · Experimental Diabetes Research · doi:10.1155/2010/213176 · Cited by 37
“Indirect evidence for a role of oxidative stress in ISDN therapy comes from the highly beneficial effects of hydralazine combination therapy [92] since hydralazine is a powerful antioxidant [93] and has been”
BackgroundPharmacological interventions for heart failure in people with chronic kidney disease
Lunney, M., Ruospo, M., Natale, P., Quinn, R. R., Ronksley, P. E., Konstantinidis, I., Palmer, S. C., Tonelli, M. A., Strippoli, G. F., & Ravani, P. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012466.pub2 · Cited by 42
Renal Function in Advanced Heart Failure
Giamouzis, G., Butler, J., & Triposkiadis, F. K. (2011) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2011.00240.x · Cited by 33
Thadani, U. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0072-5 · Cited by 38
“As such, the combination of hydralazine plus ISDN is recommended for African-American patients to reduce mortality and prevent hospitalization due to heart failure [101].”
BackgroundResultRacial differences in outcome and treatment effect in congestive heart failure
Mathew, J., Wittes, J. T., McSherry, F., Williford, W. O., Garg, R., Probstfield, J. L., & Yusuf, S. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.03.060 · Cited by 33
Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy
Mehta, R. H., Stebbins, A., Lópes, R. D., Rao, S. V., Bates, E., Pieper, K. S., Armstrong, P. W., de Werf, F. V., White, H. D., Califf, R. M., et al. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.07.028 · Cited by 33
Inter-Ethnic Differences—How Important is it in Cancer Treatment?
Ling, W. H. Y., & Lee, S. C. (2011) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v40n8p356 · Cited by 35
Alemayehu, D., Chen, Y., & Markatou, M. (2017) · Statistical Methods in Medical Research · doi:10.1177/0962280217710570 · Cited by 37
Wiggers, H., Køber, L., Gislason, G., Schou, M., Poulsen, M. K., Vraa, S., Nielsen, O. W., Bruun, N. E., Nørrelund, H., Hollingdal, M., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.09.020 · Cited by 33
Nitrate Therapy for Heart Failure
Gupta, D., Georgiopoulou, V. V., Kalogeropoulos, A. P., Marti, C. N., Yancy, C. W., Gheorghiade, M., Fonarow, G. C., Konstam, M. A., & Butler, J. (2013) · JACC Heart Failure · doi:10.1016/j.jchf.2013.03.003 · Cited by 33
Self-citationThe problem of polypharmacy in heart failure
Flesch, M., & Erdmann, E. (2006) · Current Cardiology Reports · doi:10.1007/s11886-006-0037-7 · Cited by 35
Metadata
- Authors
- Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., & Cohn, J. N.
- Affiliations
- University of Minnesota (US)
- United States Department of Veterans Affairs (US)
- The University of Texas Southwestern Medical Center (US)
- Veterans Health Administration (US)
- Xavier University of Louisiana (US)
- Association of Black Cardiologists (US)
- University of North Carolina at Chapel Hill (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-11-11
- Volume
- 351
- Issue
- 20
- Pages
- 2049-2057
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140023412
- Cited by
- 1,773
- References
- 61
- Citations by year
- 2026: 28 · 2025: 30 · 2024: 43 · 2023: 67 · 2022: 68 · 2021: 70 · 2020: 76 · 2019: 53 · 2018: 58 · 2017: 90 · 2016: 78 · 2015: 79 · 2014: 76 · 2013: 78 · 2012: 97
- FWCI
- 84.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- isosorbide dinitrate, hydralazine, advanced heart failure, Black patients, fixed-dose combination, mortality, heart failure hospitalization, quality of life, dilated ventricles
- MeSH terms
- Adult, Aged, Double-Blind Method, Drug Combinations, Drug Therapy, Combination, Female, Heart Failure, Humans, Hydralazine, Isosorbide Dinitrate, Male, Middle Aged, Quality of Life, Vasodilator Agents, Survival Analysis, Treatment Outcome, Nitric Oxide Donors, Black People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.